European MASH market growth faces access hurdles despite new therapy approvals

Spherix survey found 75% of European gastroenterologists and hepatologists see high unmet need, while more than 40% of patients are estimated to remain undiagnosed.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.